Vivalis, GlaxoSmithKline Win OK For First Human Trial With EB66
PARIS Nov 24 (Reuters) - French biotech Vivalis (VLS.PA) and its British partner GlaxoSmithKline (GSK.L) have won U.S. clearance to begin testing for the first time on humans flu vaccines that were produced using Vivalis's technology.